Inflation Reduction Act (IRA)
A flawed policy in the Inflation Reduction Act known as the “pill penalty” will have unintended consequences for patients, caregivers and providers for years to come.
A flawed policy in the Inflation Reduction Act known as the “pill penalty” will have unintended consequences for patients, caregivers and providers for years to come.
Why is this a problem?
Because pills are relatively easier to take than a shot or injection, they are often the preferred method among patients because they offer greater flexibility, affordability and convenience in managing their condition. They are also essential in the treatment of many conditions like:
The pill penalty fails to address the root causes of high out-of-pocket costs for seniors –– pharmacy benefit managers (PBMs) and insurance companies who ultimately determine how much patients pay at the pharmacy counter. Despite playing no role in the research or development of medicines, these middlemen take a significant share of every dollar spent on prescription drugs, all while standing in the way of patients and their medicines and denying access to low-cost alternatives. To truly address the issue of rising health care costs, we must hold middlemen accountable not declare a war on cures.
A bipartisan group of lawmakers in Congress has sponsored a fix to the pill penalty that would ensure patients have continued access to innovative, low-cost, convenient medicines for years to come. The Ensuring Pathways to Innovative Cures (EPIC) Act would align the timeline for eligibility for price setting for small molecules with the timeline for biologics, leveling the playing field for innovation.
The EPIC Act is a critical step toward fixing the pill penalty and ensuring that small molecule medicines remain a viable and accessible treatment option for millions of Americans. By passing this bipartisan legislation, Congress will protect patient access to innovative, affordable treatment options and reaffirm our nation’s leadership in medical innovation.
REFERENCE:
©2024 Pharmaceutical Research and Manufacturers of America, 670 Maine Avenue, SW, Suite 1000, Washington, DC 20024
Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how we and third parties use pixel tags, and how that use affects you, click here.